Arbutus Biopharma Corporation
ABUS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.64 | 1.31 | 0.14 | 0.35 |
| FCF Yield | -10.71% | -20.96% | -10.20% | -16.54% |
| EV / EBITDA | -8.36 | -5.60 | -5.22 | -4.28 |
| Quality | ||||
| ROIC | -65.47% | -63.84% | -42.82% | -37.89% |
| Gross Margin | 77.64% | -306.26% | 96.34% | 84.05% |
| Cash Conversion Ratio | 0.93 | 1.18 | 0.51 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -45.92% | 18.19% | 78.04% | 22.27% |
| Free Cash Flow Growth | 25.20% | -142.40% | 47.52% | -32.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.51 | 0.25 | 0.46 | 1.49 |
| Interest Coverage | -557.07 | -170.16 | -37.92 | -25.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.39 |
| Cash Conversion Cycle | -470.08 | 19.77 | -887.70 | -1,556.52 |